JHM Biopharma Lands Nearly 200 Million Yuan Series C Financing; WinX Capital Serves as Exclusive Financial Advisor Across Multiple Rounds

JHM Biopharmaceutical(Hangzhou) Co., Ltd.(JHM Biopharma) has wrapped up a nearly 200 million yuan Series C financing. Qiantang Heda Industrial Fund and Zhejiang Harmony Investment Management Co., Ltd.(HMC) co-led the round, while CS Capital and other investment firms came in as follow-on investors. Existing shareholders 3E Bioventures, Guangdian Capital and Hongsheng Capital also participated. WinX Capital has acted as the exclusive financial advisor for multiple consecutive financing rounds.

Capital raised in this round will primarily support ongoing research and development for the company’s candidate pipeline, speed up industrial scaling and commercialization, and further entrench JHM Biopharma’s strategic positioning in its key focus areas.

A biotech innovator focused on developing protein therapeutics and medical devices using recombinant technology, JHM Biopharma concentrates its core operations on three key areas: treatments for endocrine disorders, neurological diseases and tissue repair. Drawing on years of accumulated expertise in R&D and manufacturing, the company has built a full-lifecycle product development system. Powered by its proprietary technologies, JHM Biopharma ranks among global leaders in large-scale production techniques and manufacturing progress for its product portfolio.

The successful close of the Series C round marks strong validation from the capital market for JHM Biopharma’s technological prowess, pipeline layout and industrial capabilities, and provides robust momentum for its long-term growth.

Moving ahead, JHM Biopharma will keep recombinant technology at the core of its growth strategy. The company will advance R&D and clinical trials for its flagship pipeline, expand its product lineup to meet evolving market needs, and expedite manufacturing and commercial launches. It aims to emerge as an industry leader and deliver superior, breakthrough clinical solutions to patients worldwide.